SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001661539-23-000002
Filing Date
2023-03-21
Accepted
2023-03-21 19:10:51
Documents
1
Period of Report
2023-03-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_167944023837852.html 4  
1 FORM 4 wf-form4_167944023837852.xml 4 4986
  Complete submission text file 0001661539-23-000002.txt   6387
Mailing Address C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Trevejo Jose M. (Reporting) CIK: 0001661539 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 23750886

Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)